A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

Saved in:
Bibliographic Details
Title: A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.
Authors: Dixit KS; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA. karan.dixit@northwestern.edu.; Department of Neurology, Northwestern University, Chicago, IL, USA. karan.dixit@northwestern.edu., Kumthekar P; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Neurology, Northwestern University, Chicago, IL, USA., Lukas RV; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Neurology, Northwestern University, Chicago, IL, USA., Williams A; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Neurology, Northwestern University, Chicago, IL, USA., Tate MC; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Neurosurgery, Northwestern University, Chicago, IL, USA., Chandler JP; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Neurosurgery, Northwestern University, Chicago, IL, USA., Jamshidi P; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Pathology, Northwestern University, Chicago, IL, USA., Helenowski I; Biostatistics Collaborative Core, Loyola University, Chicago, IL, USA., Zhang H; Department of Preventive Medicine, Northwestern University, Chicago, IL, USA., Bloch O; Department of Neurosurgery, University of California, Davis, Sacramento, CA, USA., Raizer JJ; Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.; Department of Neurology, Northwestern University, Chicago, IL, USA.
Source: Journal of neuro-oncology [J Neurooncol] 2026 Jan 28; Vol. 176 (3), pp. 185. Date of Electronic Publication: 2026 Jan 28.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7373
DOI:10.1007/s11060-026-05446-1